A non-progressive disorder cerebral palsy (CP) occurs as a result of the damage to the brain of a fetus and newborns. It is estimated to affect everyone in 323 children in the U.S. The Gross Motor Function Classification System (GMFCS) has been a validated and reliable tool used for assessing the gross motor function in patients with CP. However, the use of tool has been found to be limited in assessing certain symptoms of CP that are essential to be evaluated. Our study aimed at developing a scoring system that can assess the symptoms which remained untouched in GMFCS. NFS appears to be a unique tool that can be used globally to assess the improvement in patients with CP.
ReoStem
The future of allogenic stem cells
